Published on 09/12/2025

Supporting AET in Regulatory Submissions: Language That Works

Understanding Extractables and Leachables (E&L)

In the pharmaceutical industry, ensuring the safety and efficacy of drug products is paramount. A critical component of this assurance exists in the context of extractables and leachables (E&L) studies, especially when considering how materials used in packaging and delivery systems can interact with drug products. E&L assesses the risk associated with contaminants that could migrate from packaging into the drug product, potentially affecting its integrity and safety.

The USP guidance provides a clear framework on container closure integrity (CCI) and how manufacturers can establish the suitability of packaging materials. Particularly, with the new revisions in EU GMP Annex 1, the industry is urged to incorporate systematic approaches to evaluate the risks associated with E&L, focusing on actual use contexts. Comprehensive E&L risk assessment must be in alignment with global regulatory expectations from authorities such as FDA, EMA, and MHRA.

The fundamental goal of conducting E&L studies is to establish an analytical evaluation threshold (AET) which serves as a benchmark for evaluating the acceptability of leakages that might contaminate drugs under conditions of use. Understanding AET is crucial, as it defines the threshold levels below which substances can be considered non-harmful based on their daily exposure.

Establishing the Analytical Evaluation Threshold (AET)

The AET is built on the premise that certain extractables and leachables don’t pose a significant risk if their concentrations in the final product are below a defined threshold, which is typically derived from established toxicological data or from calculations based on typical daily doses. The following steps outline the process of calculating AET:

1. Identify Relevant Toxicological Data: Gather data on known toxicological effects of potential leachables. Sources include toxicology databases, scientific literature, and regulatory documents.
2. Determine Daily Exposures: Based on expected usage patterns of the product, determine the estimated daily exposure (EDE) for each extractable or leachable compound.
3. Calculate the AET: Divide the no observed adverse effect level (NOAEL) or reference dose (RfD) by the EDE to yield the AET for each substance.
4. Compile the Results: Document AET calculations, specifying assumptions made, data sources, and the rationale for chosen values.

This calculated threshold becomes integral to your risk assessment to communicate effectively with regulatory bodies.

Best Practices for E&L Studies and AET Documentation

When preparing E&L studies for regulatory submissions, the documentation must be comprehensive, emphasizing scientific rigor and transparency. The following best practices should be followed:

• Detailed Study Protocols: Ensure protocols are robust and clearly state sampling, analytical methods, and environmental conditions that mimic intended product storage.
• Robust Analytical Methods: Choose analytical techniques that can achieve required sensitivity and specificity such as LC-MS or GC-MS. Methods must comply with standards from organizations like USP.
• Replicate Studies: Conduct replicate studies to demonstrate reproducibility in E&L data and bolster the validity of results.
• Risk Assessment Integration: Incorporate AET calculations directly into the E&L assessment, bridging the gap between raw data and acceptable limits.

Employing these best practices not only aids in fulfilling regulatory requirements but also builds a defensible case for AET levels defined in your submissions.

Container Closure Integrity and Single-Use Systems Validation

Container closure integrity (CCI) testing is an indispensable part of ensuring that E&L assessments yield valid results. The methodology ensures that containers are properly sealed and that there are no leaks capable of permitting the ingress of contaminants. The various approaches to CCI verification include:

1. Microbial Challenge Testing: Expose the closure system to microbial contaminants under specified conditions to evaluate the closure’s ability to maintain sterility.
2. Physical Integrity Tests: Utilize methods such as vacuum decay or helium leak testing to assess the integrity of the container.
3. Environmental Testing: Conduct evaluations under various storage conditions to simulate real-world scenarios, ensuring consistent results across temperature, humidity, and pressure variations.

For single-use systems validation, the same principles apply, but special attention must be given to the unique configurations and materials involved in one-time-use scenarios. Collaboration in pre-validated systems from manufacturers can save time and effort in AET establishment since many data points may already exist.

Regulatory Considerations and Alignment with Global Standards

Understanding the regulatory landscape is crucial when preparing E&L studies, AET documentation, and CCI testing. The guidelines issued by the major regulatory bodies provide structured frameworks to follow. For example:

• FDA Guidance: The FDA highlights the importance of scientific methods in determining AET, demanding a thorough examination of risk associated with food contact substances and their safety.
• EU GMP Annex 1: European Union guidelines emphasize the need for stringent checks in process that may affect product sterility, enhancing the need for comprehensive E&L studies.
• PQRI Guidelines: The Product Quality Research Institute (PQRI) provides valuable insights into establishing frameworks for evaluating E&L that can inform test strategies and documentation for AET.

Engagement with these standards ensures not only compliance but fosters trust among regulators in the submitted materials.

Conclusion: Defensible Practices and Collaborative Approach

In conclusion, supporting AET during regulatory submissions requires a systematic approach that adheres to the rigorous expectations set by global regulatory bodies. A robust understanding of extractables and leachables along with methods for AET calculation and CCI testing is imperative for pharmaceutical professionals in their compliance efforts. By developing comprehensive study protocols, employing best practice methodologies, and aligning with regulatory expectations, organizations can create defensible documentation that supports successful approvals.

The evolving landscape of regulatory submissions necessitates an equally evolving approach to risk assessment concerning E&L and single-use systems validation, demanding an integrated and collaborative effort across departments. This effort ensures that the pharmaceutical products remain safe for patient use, thereby maintaining high standards in the industry.